Premium
A new combination chemotherapy for advanced chronic lymphocytic leukemia (vincristine, cyclophosphamide, melphalan, peptichemio, and prednisone protocol)
Author(s) -
Ferrara Felicetto,
Vecchio Luigi Del,
Mele Giuseppina,
Rametta Vincenzo,
Ronconi Fioravante,
Montuori Renato
Publication year - 1989
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19890815)64:4<789::aid-cncr2820640403>3.0.co;2-v
Subject(s) - medicine , chlorambucil , vincristine , cyclophosphamide , melphalan , prednisone , chronic lymphocytic leukemia , chemotherapy , leukemia , oncology , gastroenterology
The MiNa protocol (vincristine, cyclophosphamide, melphalan, peptichemio, and prednisone) was given to 20 patients with advanced B‐cell chronic lymphocytic leukemia. Complete remission (absence of all clinical and bone marrow evidence of leukemia) was obtained in 35% of cases; partial response ( > 50% reduction in organ enlargement and decreasement of lymphocyte count to less than 15 9 × 10/1) was observed in 35% of patients. Of 12 patients (60%) previously treated with chlorambucil and corticosteroids, nine responded to treatment. Toxicity was mild and the relapse rate particularly low. It was concluded that the MiNa protocol represents an effective chemotherapy for advanced and/or progressive CLL.